A Newcastle University project that gauges whether health technologies can deliver real changes to the NHS has claimed £22 million (nearly $30 million) in funding from the UK National Institute for Health and Care Research (NIHR). Newcastle’s NIHR Innovation Observatory was set up nearly a decade ago to identify emerging medicines, diagnostics, devices, and digital…
Sanofi’s BTK inhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Wayrilz (rilzabrutinib) has been cleared by the US regulator for adults with persistent or chronic ITP who have had an insufficient response to a previous treatment. In ITP,…
Eisai and Biogen have won FDA approval for a subcutaneous injection version of Leqembi that could help accelerate uptake of the Alzheimer’s disease therapy. The green light for Leqembi Iqlik (lecanemab) means it can be used as an alternative to infusions during the maintenance phase of treatment with the anti-amyloid therapy, and patients will still…
Eli Lilly has paused shipments of its type 2 diabetes and weight loss therapy Mounjaro to the UK, ahead of a price increase next month that has reportedly led patients to start stockpiling the drug. The company said in mid-August that it would raise the list price of dual GLP-1/GIP agonist Mounjaro (tirzepatide) in the…
German pharma company Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year. Stada chief executive Peter Goldschmidt has said that the company will go for an initial public offering (IPO) in the coming months “provided the general conditions are right,” according…
Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines. An unusual study presented at the European Society of Cardiology (ESC) congress in Madrid today has found that treating heart failure patients with GLP-1s not only improved clinical outcomes, but also reduced greenhouse gas emissions, medical…
Pharma commercialisation services provider EVERSANA (pharmaphorum’s parent company) has acquired Waltz Health, a Chicago digital health company offering AI-driven marketplaces to lower overall drug costs. The terms of the deal were not disclosed. As part of the deal, Waltz Health CEO and co-founder Mark Thierer – who has previously led OptumRx and Catamaran – will…
Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for regulatory filings around the world. The results of the ATTAIN-2 study, which involved people with obesity or overweight with type 2 diabetes, showed that the oral GLP-1 agonist achieved an average weight loss of…
Roche’s Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 billion investment in the US. The plant – its first on the East Coast of the US – is a 65,000 sq m unit located in Holly Springs that will be used to support the…
Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen’s much-delayed drug for early-stage Alzheimer’s disease. Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday (1st September), becoming the first drug in the class to reach…